Indeed FFAR2 holds promise for the management of Inflammatory Bowel Disease (IBD) (298) a possible side-effect of anti-diabetic treatment with DPP-IV inhibitors (299). This evidence concerns the gene FFAR2 and inflammatory bowel disease.